Document:

Exhibit 10.25

 

AMENDED AND RESTATED NOTE PURCHASE AGREEMENT

 

This
AMEDNED AND RESTATED NOTE PURCHASE Agreement (this “Agreement”) is made as of June 2, 2014 by and among
CNS Response, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto
(each, an “Investor” and together, the “Investors”).

 

RECITALS

 

whereas,
the Company entered into that certain Note Purchase Agreement, dated as of September 22, 2014, with those certain investors
named therein (the "Original Agreement");

 

WHEREAS, the Company entered into that
certain Amendment No. 1 to the Note Purchase Agreement, dated as of April 14, 2015,with those certain investors named therein ("Amendment
No. 1"), to increase the aggregate amount of notes issuable thereunder, and extend the period of time by which the Company
was permitted to complete such fundraising; and

 

WHEREAS, this Agreement amends and restates
the Original Agreement solely to update for the revisions provided by Amendment No. 1.

 

NOW, THEREFORE, in consideration for
the mutual promises and covenants herein, the parties agree as follows:

 

Agreement

 

Section
1 – Purchase and Sale of Notes

 

1.1          Purchase
and Sale of Notes.  The Company has authorized the issuance and sale, in accordance with the terms hereof, of Secured
Convertible Promissory Notes in the amended aggregate principal amount of up to $3,000,000 (the “Note Cap Amount”),
substantially in the form attached as Exhibit A hereto (individually, a “Note” and, collectively, the
“Notes”).  On the terms and subject to the conditions set forth in this Agreement, at the Closings
(as defined below) the Company agrees to issue to each Investor, and each Investor agrees to purchase from the Company, a Note
in the principal amount set forth on Schedule A hereto for the aggregate consideration set forth opposite such Investor’s
name on Schedule A hereto. The financing pursuant to which the Company is issuing the Notes is hereinafter referred to
as the “Financing”.

 

1.2          Closings.  

 

(a)          Initial
Closing.  The initial purchase and sale of the Notes shall take place at a closing (the “Initial Closing”)
which shall take place remotely via exchange of documents and signatures at such time and place as may be agreed to among the Company
and the Investors.  At the Initial Closing, the Company shall deliver to each of the Investors purchasing Notes for cash
at such closing a Note in the face amount set forth opposite such Investor’s name on Schedule A under the column entitled
“Purchase Price / Principal Amount of Note (Initial Closing)” against receipt of a check subject to collection or a
wire transfer in immediately available funds of the purchase price, to an account designated by the Company.   

 

    	 

     

    

 

(b)          Additional
Closings.  The Company shall have the right, on one or more occasions, to hold additional closings (each, an “Additional
Closing”, and collectively with the Initial Closing, the “Closings”,
and individually, a “Closing”), pursuant to which it shall have the right
to issue and sell additional Notes to additional Investors or existing Investors (provided that no Additional Closings shall take
place later than September 30, 2015).  At each Additional Closing, the Company shall deliver to each Investor purchasing
Notes for cash at such closing a Note in the face amount of the purchase price paid by such Investor for such Note, against receipt
of a check subject to collection or a wire transfer in immediately available funds of the purchase price, to an account designated
by the Company. By receiving a Note at an Additional Closing, each Investor receiving such Notes represents that its representations
and warranties contained in Section 3 are true and correct as of the date of such Additional Closing.  The aggregate
amount of Notes that may be issued at Closings hereunder shall in no event exceed the Note Cap Amount.  The Company shall
have the right to update Schedule A in order to add information regarding Additional Closings, which shall not be deemed
to be an amendment to this Agreement.

 

The obligation of each Investor to purchase
and pay for the Notes to be delivered at a Closing is, unless waived by such Investor, subject to the condition that the Company’s
representations and warranties contained in Section 2 are true, complete and correct on and as of such Closing date.  The
obligation of the Company to sell and issue Notes to be delivered at a Closing is, unless waived by the Company, subject to the
condition that the relevant Investor’s representations and warranties contained in Section 3 are true, complete and correct
on and as of the applicable Closing date.

 

1.3          Security
Agreement.  At the Initial Closing, the Company shall execute and deliver to the Investors a Security Agreement substantially
in the form of Exhibit B attached hereto (the “Security Agreement”).

 

1.4          Registration
Rights Agreement.  At the Initial Closing, the Company shall execute and deliver to the Investors a Registration
Rights Agreement substantially in the form of Exhibit C attached hereto (the “Registration Rights Agreement”).

 

Section
2 - Representations and Warranties

of
the Company

 

The Company represents
and warrants to each Investor as follows:

 

2.1          Organization,
Good Standing and Qualification.  The Company is a corporation duly organized and validly existing under the laws
of the State of Delaware.  The Company has the requisite corporate power to own and operate its properties and assets
and to carry on its business as now conducted and as proposed to be conducted.

 

    	2

     

    

 

2.2          Authority
to Execute.  The execution, delivery and performance by the Company of (i) this Agreement, (ii) the  Notes
to be issued pursuant to the terms of this Agreement, (iii) the Security Agreement, (iii) the Registration Rights Agreement, and
(iv) any financing statements thereunder (collectively, the “Loan Documents”) are within the Company’s
corporate powers, have been duly authorized by all necessary corporate action, do not and will not conflict with any provision
of law or organizational document of the Company (including its Certificate of Incorporation or Bylaws) or of any agreement or
contractual restrictions binding upon or affecting the Company or any of its property and need no further stockholder or creditor
consent.

 

2.3          No
Stockholder Approval Required.  No approval of the Company’s stockholders is required for (i) the entry by
the Company into this Agreement, (ii) the issuance of the Notes contemplated by this Agreement, or (iii) the issuance of any shares
of stock upon conversion of the Notes.

 

2.4          Valid
Issuance.  The shares of stock to be issued upon conversion of the Notes contemplated by this Agreement (the “Conversion
Securities” and together with the Notes, the “Securities”) will be, upon conversion and exercise in
accordance with the terms of the Notes, as applicable, validly issued, fully paid and nonassessable and free of restrictions on
transfer other than restrictions on transfer under the Loan Documents, the documents entered into by the investors and other parties
in the financing giving rise to repayment of the Notes, applicable state and federal securities laws and liens or encumbrances
created by or imposed by the Investor.  Assuming the accuracy of the representations of the Investor in Section 3 of
this Agreement, the Securities will be issued in compliance with all applicable federal and state securities laws.

 

2.5          Binding
Obligation.  This Agreement is, and the other Loan Documents when delivered hereunder will be, legal, valid and binding
obligations of the Company enforceable against the Company in accordance with their respective terms, subject, as to enforcement
of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights
generally and to general equitable principles.

 

2.6          Litigation.  Other
than as disclosed in the Company’s SEC Reports (as defined below), no litigation or governmental proceeding is pending or
threatened against the Company which may have a materially adverse effect on the financial condition,  operations or
prospects of the Company, and to the knowledge of the Company, no basis therefore exists.

 

2.7          Intellectual
Property.  The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade
names, copyrights, trade secrets, licenses, information and other proprietary rights and processes (“Intellectual Property”)
necessary for its business as now conducted and as presently proposed to be conducted, without any infringement of the rights of
others.  Schedule B contains an accurate and complete list of all Intellectual Property owned by the Company or any of
its subsidiaries. The use by the Company or its subsidiaries of Intellectual Property owned or purported to be owned by the Company
or its subsidiaries and the general conduct and operations of the business of the Company and its subsidiaries does not violate,
infringe, misappropriate or misuse any Intellectual Property rights of any third party. To the knowledge of the Company, no third
party is currently infringing, misappropriating or otherwise violating, or has infringed or misappropriated or otherwise violated,
rights of any of the Company or its subsidiaries in any Intellectual Property owned, licensed, used, or held for us by the Company
or its subsidiaries. There are no outstanding options, licenses or agreements of any kind relating to the foregoing proprietary
rights, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes
of any other person or entity other than such licenses or agreements arising from the purchase of “off the shelf” or
standard products.

 

    	3

     

    

 

2.8          SEC
Reports.  The Company has timely filed all forms, reports, schedules, proxy
statements, registration statements and other documents (including all exhibits thereto) required to be filed by it with the Securities
and Exchange Commission (the “SEC”) pursuant to the federal securities laws and the SEC rules and regulations
thereunder, together with all certifications required pursuant to the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley
Act”) (as they have been amended since the time of their filing, including all exhibits thereto, the “SEC Reports”).  Each
of the SEC Reports complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended
(the “Securities Act”) and the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act and the rules
and regulations of the SEC under all of the foregoing. None of the SEC Reports contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading.  

 

Section
3 - Representations and Warranties

of
the Investors

 

Each Investor represents
and warrants to the Company as follows:

 

3.1          Authorization;
Binding Obligations.  The Investor has full power and authority to enter into this Agreement and each of the other
Loan Documents to which he, she or it is a party, and this Agreement and each other Loan Document constitutes a valid and legally
binding obligation of each Investor, enforceable against each Investor in accordance with its terms, subject, as to enforcement
of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights
generally and to general equitable principles.

 

3.2          Accredited
Investor.  The Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation
D promulgated under the Securities Act.

 

3.3          Investment
for Own Account.  Each Investor represents that it (i) is acquiring the Securities solely for its own account and
beneficial interest for investment and not with a view to, or for resale in connection with, any distribution or public offering
thereof within the meaning of the Securities Act, and (ii) has no present intention of selling (in connection with a distribution
or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate
a change in such intention.  

 

    	4

     

    

 

3.4          Information
and Sophistication.  Without limiting the representations and warranties of the Company set forth in Section 3, each
Investor hereby: (a) acknowledges that it has received all the information it has requested from the Company and it considers necessary
or appropriate for deciding whether to acquire the Securities, (b) represents that it has had an opportunity to ask questions and
receive answers from the Company regarding the terms and conditions of the offering of the Securities and to obtain any additional
information necessary to verify the accuracy of the information given the Investor and (c) further represents that it has such
knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of this investment.

 

3.5          Ability
to Bear Economic Risk.  Each Investor acknowledges that investment in the Securities involves a high degree of risk,
and represents that it is able, without materially impairing its financial condition, to hold the Securities for an indefinite
period of time and to suffer a complete loss of its investment.

 

3.6          U.S.
Person.  Each Investor is a U.S. Person as defined under Regulation S under the Securities Act, as amended, which
definitions are attached hereto as Appendix I, or such Investor will make such representations and warranties, and agree
to such covenants and restrictions as set forth in Section 3.7 below.

 

3.7          Representations
and Warranties of Non-US Investors; Covenants of and Restrictions Thereon.

 

(a)          Representations
and Warranties.  If Investor cannot represent and warrant that it is a U.S. Person (as defined in Appendix I hereto),
such Investor (a “Foreign Investor”) hereby represents and warrants to the Company as follows:

 

(i)          The
Securities being purchased are being acquired for investment for Foreign Investor’s own account, not as a nominee or agent,
and not for the account or benefit of, a U.S. Person (as defined in Appendix I hereto), and not with a view to the resale or distribution
of any part thereof in the United States (as defined in Appendix I hereto) or to a U.S. Person, and that Foreign Investor has no
present intention of selling, granting any participation in, or otherwise distributing such Securities.

 

(ii)         Foreign
Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations
to such person or to any third person in the United States or to a U.S. Person, or any hedging transaction with any third person
in the United States or to a United States resident, with respect to any of the Securities.

 

(iii)        Foreign
Investor understands that the Securities are not registered under the Securities Act on the ground that the sale provided for in
this Agreement and the issuance of securities hereunder is exempt from registration under the Securities Act pursuant to Regulation
S thereof, and that the Company’s reliance on such exemption is predicated on the Foreign Investors’ representations
set forth herein.

 

(iv)        Foreign
Investor is a person or entity that is not a U.S. Person

 

    	5

     

    

 

(b)          Covenants.  Each
Foreign Investor hereby agrees that:

 

(i)          Foreign
Investor will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy,
purchase or otherwise acquire or take a pledge of) any of the Securities purchased hereunder except in compliance with the Securities
Act, applicable blue sky laws, and the rules and regulations promulgated thereunder; provided that in a transaction exempt from
registration under the Securities Act, such Foreign Investor shall, prior to effecting such disposition, provide notice to the
Company of such proposed disposition and if reasonably requested by the Company submit to the Company an opinion of counsel in
form and substance reasonably satisfactory to the Company to the effect that the proposed transaction is in compliance with the
Securities Act.

 

(c)          Legend
Requirements. Each certificate representing the Securities issued to a Foreign Investor shall (unless otherwise permitted by
the provisions of the Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition
to any legend required under applicable state securities laws or as provided elsewhere in this Agreement):

 

“THE SECURITIES REPRESENTED HEREBY
HAVE BEEN ACQUIRED PURSUANT TO REGULATION S OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD,
MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE THEREWITH, PURSUANT TO A REGISTRATION UNDER THE
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT
AND ANY APPLICABLE STATE SECURITIES LAWS.  IN ADDITION, NO HEDGING TRANSACTION MAY BE CONDUCTED WITH RESPECT TO THESE
SECURITIES UNLESS SUCH TRANSACTIONS ARE IN COMPLIANCE WITH THE ACT.”

 

(d)          Stop-Transfer
Restrictions.  The Company hereby agrees, for the benefit of the Investors, that it will not register any transfer
of the Securities not made in accordance with the provisions of Regulation S, pursuant to registration under the Securities Act,
or pursuant to an available exemption from registration.

 

3.8          Further
Assurances.  Each Investor agrees and covenants that at any time and from time to time it will promptly execute and
deliver to the Company such further instruments and documents and take such further action as the Company may reasonably require
in order to carry out the full intent and purpose of this Agreement and to comply with state or federal securities laws or other
regulatory approvals.

 

Section
4 - Miscellaneous

 

4.1          Conditions
Precedent.  The obligation of each Investor to consummate the transactions contemplated hereby is subject, at the
option of each Investor, to the fulfillment of the following conditions, any one or more of which may be waived by each Investor:

 

(a)          execution
of the Notes at each Closing;

 

    	6

     

    

 

(b)          approval
of the Company’s Board of Directors of the transactions contemplated hereby and all other actions necessary for the consummation
of the transactions contemplated hereby at the Initial Closing;

 

(d)          the
Company and each Investor shall have entered into the Registration Rights Agreement and the Security Agreement; and

 

(e)          the
Company shall have completed the filing of a UCC-1 financing statement with respect to the Collateral (as defined in the Security
Agreement) at the Initial Closing.

 

4.2          No
Waiver; Cumulative Remedies.  No failure or delay on the part of any party to any Loan Document in exercising any
right or remedy under, or pursuant to, any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise
of any such right, remedy or power preclude other or further exercise thereof, or the exercise of any other right, remedy or power.  The
remedies in the Loan Documents are cumulative and are not exclusive of any remedies provided by law.

 

4.3          Amendments
and Waivers.  Except as otherwise expressly set forth in this Agreement, any term of this Agreement may be amended
(either retroactively or prospectively) with the written consent of (x) the Company and (y) and those Investors holding Notes whose
aggregate principal amount represents a majority of the total outstanding principal amounts of all then outstanding Notes under
this Agreement, which includes RSJ Private Equity uzavreny investicni fond a.s. (“RSJ”) for so long as RSJ is
the holder of an outstanding Note (collectively, the “Majority Holders”); provided that no such amendment may
discriminate against a holder of Notes in a manner different from the other holders without such holder’s written consent.  Any
amendment effected in accordance with this Section 4.3 shall be binding upon each Investor, each future holder of Securities and
the Company.

 

4.4          Notices.  
Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement
shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered to the other party; (b) when
sent by telecopier, facsimile or email transmission to the contact information set forth below if sent between 8:00 a.m. and 5:00
p.m. recipient’s local time on a Business Day (as defined below), or on the next Business Day if sent by telecopier, facsimile
or email transmission to the contact information set forth below if sent other than between 8:00 a.m. and 5:00 p.m. recipient’s
local time on a Business Day; (c) two Business Days after deposit in the U.S. mail with first class or certified mail receipt requested
postage prepaid and addressed to the other party at the address set forth below its name on the signature page hereto; or (d) the
next Business Day after deposit with a national overnight delivery service, postage prepaid, addressed to each of the parties as
set forth below its name on the signature page hereto with next Business Day delivery guaranteed, provided that the sending party
receives a confirmation of delivery from the delivery service provider:

 

If to the Company, to:

 

CNS Response, Inc.

 

    	7

     

    

 

85 Enterprise, Suite 410

Attention: Paul Buck, Chief
Financial Officer

Fax: (866) 294-2611

eMail: pbuck@cnsresponse.com

 

If to an Investor, to the
contact information provided in Schedule A.

 

A party may change or supplement
its address for notice, or designate additional addresses, for purposes of this Section 4.4 by giving the other parties written
notice of the new address in the manner set forth above.  For purposes of this Section 4.4, “Business Day”
shall mean any day which is not a Saturday or Sunday or a legal holiday on which banks are authorized or required to be closed
in Los Angeles, California or Czech Republic.

 

4.5          Costs
and Expenses.  The Company and each Investor agree to be responsible for their own costs and expenses incurred in
connection with the preparation of the Loan Documents.  If any litigation, contest, dispute, suit, proceeding or action
is instituted between or among any of the parties hereto regarding the enforcement or interpretation of this Agreement or any of
the Exhibits hereto, the prevailing party shall be entitled to reimbursement from the other party or parties for all reasonable
expenses, costs, charges and other fees (including legal fees) incurred in connection with or related to such dispute.

 

4.6          Governing
Law.  The Loan Documents shall be governed by and construed in accordance with the laws of the State of California,
without regard to the conflicts of law provisions of the State of California or of any other state.  The Company and
each Investor consent to personal jurisdiction in Orange County, California.

 

4.7          Severability.  If
any term in this Agreement is held to be illegal or unenforceable, the remaining portions of this Agreement shall not be affected,
and this Agreement shall be construed and enforced as if this Agreement did not contain the term held to be illegal or unenforceable.

 

4.8          Binding
Effect; Assignment.  The Loan Documents shall be binding upon and inure to the benefit of the Company and each Investor
and their respective successors and assigns.  The Company may not assign its rights or interest under the Loan Documents
without the prior written consent of the Majority Holders.

 

4.9          Transfer
of Securities.  Notwithstanding the legend required to be placed on the Securities by applicable law, no registration
statement or opinion of counsel shall be necessary: (a) for a transfer of Securities to the respective estate of each Investor
or for a transfer of Securities by gift, will or intestate succession of each Investor to his or her spouse or to the siblings,
lineal descendants or ancestors each Investor or his or her spouse, if the transferee agrees in writing to be subject to the terms
hereof to the same extent as if he or she were the original Investor hereunder; or (b) for a transfer of Securities pursuant to
SEC Rule 144 or any successor rule, or for a transfer of Securities pursuant to a registration statement declared effective by
the SEC under the Securities Act relating to the Securities.

 

    	8

     

    

 

4.10        Survival
of Representations and Warranties.  The representations and warranties of the parties contained in or made pursuant
to this Agreement shall survive the execution and delivery of this Agreement indefinitely, and shall in no way be affected by any
investigation of the subject matter thereof made by or on behalf of the other parties.

 

4.11        California
Commissioner of Corporations.  THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED
WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR PAYMENT OR RECEIPT OF ANY
PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM
QUALIFICATIONS BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE.  THE RIGHTS OF ALL PARTIES TO THIS
AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

 

[Remainder of Page Intentionally Left Blank]

 

    	9

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of
the date first written above.

 

	 	CNS RESPONSE, INC.
	 	 	 
	 	By:		 
	 	 	Name: 	Paul
    Buck
	 	 	Title:	Chief Financial Officer

 

[SIGNATURE PAGE TO AMENDED AND RESTATED NOTE PURCHASE AGREEMENT]

 

     

     

    

 

	 	INVESTOR:
	 	 	 	 
	 	By:		 
	 	 	Name: 	 
	 	 	Title:	 

 

[SIGNATURE PAGE TO AMENDED AND RESTATED NOTE PURCHASE AGREEMENT]

 

     

     

    

  

SCHEDULE A

 

	Investor	 	Purchase
        Price / Principal

        Amount
        of Note

	 	 	 
	Name:  	 	  

	 	 	 
	Address:	 	 
	 	 	 
	Fax: 	 	$______________
	 	 	 
	Email:	 	 
	 	 	 
	Tax
    ID:  	 	 
	 	 	 
	TOTAL:	 	$______________

 

     

     

    

 

EXHIBIT A

 

FORM OF NOTE

 

     

     

    

 

EXHIBIT B

 

SECURITY AGREEMENT

 

     

     

    

 

EXHIBIT C

 

REPRESENTATIVE SECURED PARTY AGREEMENT

 

     

     

    

 

EXHIBIT D

 

REGISTRATION RIGHTS AGREEMENT

 

     

     

    

 

APPENDIX I

 

CERTAIN DEFINITIONS

 

As used in the Agreement, the following terms
shall have the meanings indicated:

 

“U.S. Person”:

 

(a)          “U.S.
person” means:

 

(i)          Any
natural person resident in the United States;

 

(ii)         Any
partnership or corporation organized or incorporated under the laws of the United States;

 

(iii)        Any
estate of which any executor or administrator is a U.S. person;

 

(iv)        Any
trust of which any trustee is a U.S. person;

 

(v)         Any
agency or branch of a foreign entity located in the United States;

 

(vi)        Any
non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit
or account of a U.S. person;

 

(vii)       Any
discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated,
or (if an individual) resident in the United States; and

 

(viii)      Any
partnership or corporation if:

 

(A)         Organized
or incorporated under the laws of any foreign jurisdiction; and

 

(B)         Formed
by a U.S. person principally for the purpose of investing in securities not registered under the Act, unless it is organized or
incorporated, and owned, by accredited investors (as defined in §230.501(a)) who are not natural persons, estates or trusts.

 

(b)          The
following are not “U.S. persons”:

 

(i)          Any
discretionary account or similar account (other than an estate or trust) held for the benefit or account of a non-U.S. person by
a dealer or other professional fiduciary organized, incorporated, or (if an individual) resident in the United States;

 

(ii)         Any
estate of which any professional fiduciary acting as executor or administrator is a U.S. person if:

 

     

     

    

  

(A)         An
executor or administrator of the estate who is not a U.S. person has sole or shared investment discretion with respect to the assets
of the estate; and

 

(B)         The
estate is governed by foreign law;

 

(iii)        Any
trust of which any professional fiduciary acting as trustee is a U.S. person, if a trustee who is not a U.S. person has sole or
shared investment discretion with respect to the trust assets, and no beneficiary of the trust (and no settler if the trust is
revocable) is a U.S. person;

 

(iv)        An
employee benefit plan established and administered in accordance with the law of a country other than the United States and customary
practices and documentation of such country;

 

(v)         Any
agency or branch of a U.S. person located outside the United States if:

 

(A)         The
agency or branch operates for valid business reasons; and

 

(B)         The
agency or branch is engaged in the business of insurance or banking and is subject to substantive insurance or banking regulation,
respectively, in the jurisdiction where located; and

 

(vi)        The
International Monetary Fund, the International Bank for Reconstruction and Development, the Inter-American Development Bank, the
Asian Development Bank, the African Development Bank, the United Nations, and their agencies, affiliates and pension plans, and
any other similar international organizations, their agencies, affiliates and pension plans.

 

“United States”: the United
States of America, its territories and possessions, any State of the United States, and the District of Columbia.Exhibit 10.26

 

OMNIBUS AMENDMENT

 

This OMNIBUS AMENDMENT (this "Amendment"),
dated as of September 14, 2015, hereby amends: (i) the Note Purchase Agreement, made as of September 22, 2014, as amended by Amendment
No. 1 to the Note Purchase Agreement on April 14, 2015 (the "Agreement"), by and among CNS Response, Inc., a Delaware
corporation (the "Company"), and the investors listed on Schedule A thereto (each, an "Investor,"
and together, the "Investors"), and (ii) the Secured Convertible Promissory Notes purchased and sold pursuant
to the Agreement (individually, a "Note" and, collectively, the "Notes"); each as set forth below.  Certain
capitalized terms used but not defined herein have the meanings assigned to them in the Agreement.

 

WHEREAS, Section 4.2 of the Agreement provides
for the amendment of the Agreement in accordance with the terms set forth therein; and

 

WHEREAS, Section 8(d) of the Notes provides
for the amendment of the any term of the Notes in accordance with the terms set forth therein; and

 

WHEREAS, the Company desires to amend the Agreement
and the Notes to set the conversion price of all Notes purchased and sold pursuant to the Agreement, both those that have been
purchased and sold before the date of this Amendment and those that may be purchased and sold at any time thereafter, in the event
of a qualified financing conversion or a voluntary conversion, at $0.05 per share (as adjusted for stock splits, stock dividends,
combinations or the like affecting the Common Stock); and

 

WHEREAS, the Investors executing this Amendment
constitute the Majority Holders and hold Notes whose aggregate principal amount represents a majority of the total outstanding
principal amounts of all the current outstanding Notes under the Agreement, including RSJ Private Equity uzavreny investicni fond
a.s.; and

 

WHEREAS, in accordance with Section 8(d) of
the Notes and Section 4.2 of the Agreement, the Company and the Investors executing this Amendment now desire to amend the Agreement
and the Notes in accordance with the terms set forth herein.

 

NOW, THEREFORE, in consideration of the mutual
agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Company and the Investors executing this Amendment agree as follows:

 

Section 1.1           Amendment
to Section 2.  Section 2 of the Notes and Section 2 of the form of Note which is attached
as Exhibit A to the Agreement (the "Form Note") is hereby amended by replacing the first sentence as follows:

 

"In the event that
Company issues and sells shares of its Equity Securities (as defined below) to investors (the “Investors”) on
or before the Maturity Date in an equity financing with total proceeds to the Company of not less than $5,000,000 (excluding the
conversion of the Notes, other convertible indebtedness or other debt) (a “Qualified Financing”), then the outstanding
principal balance and accrued interest of this Note (together, the “Conversion Amount”) shall automatically
convert in whole without any further action by the Holders into a number of shares of Equity Securities equal to the quotient of
the Conversion Amount divided by a conversion price of $0.05 per share (as adjusted for stock splits, stock dividends, combinations
or the like affecting the Company’s common stock (“Common Stock”))."

 

     

     

    

  

Section 1.2           Amendment
to Section 3.  Section 3 of the Notes and Section 3 of the Form Note is hereby amended and restated in its entirety
as follows:

 

"3.          Voluntary
Conversion.  Within the period of fifteen (15) days prior to the Maturity Date the Holder shall have an option to
convert this Note into shares of Common Stock at a price equal to $0.05 per share (as adjusted for stock splits, stock dividends,
combinations or the like affecting the Common Stock)."

 

Section 1.3           No
Further Amendment.  Except as expressly amended by this Amendment, the Agreement and the Notes are in all respects
ratified and confirmed and all the terms, conditions, and provisions thereof shall remain in full force and effect. This Amendment
is limited precisely as written and shall not be deemed to be an amendment to any other term or condition of the Agreement, of
the Notes or any of the documents referred to therein.

 

Section 1.4           Effect
of Amendment.  This Amendment shall amend and form a part of the Agreement and the Notes for all purposes and is
expressly incorporated into the Agreement and the Notes, and the Company and each party hereto shall be bound hereby. From and
after the execution of this Amendment by the parties hereto, any references to the Agreement or the Notes shall be deemed a reference
to the Agreement or the Notes as amended hereby. This Amendment shall be deemed to be in full force and effect from and after the
execution of this Amendment by the parties hereto.  To the extent that any term or provision of this Amendment may be
deemed expressly inconsistent with any term or provision in the Agreement or the Notes, the terms and provisions of this Amendment
shall control.

 

Section 1.5           Entire
Agreement.  Subject to Section 1.4 of this Amendment, the Agreement and the Notes, as amended by this Amendment,
constitute the complete understanding of the Company and the Investors, regarding the subject matter hereof and supersede any and
all other agreements, either oral or in writing, between the Company and the Investors with respect to the subject matter hereof
and thereof, and no other statement or promise relating to the subject matter hereof or thereof which is not contained herein or
therein, shall be valid or binding.

 

Section 1.6           Other
Provisions.  The following sections of the Agreement are hereby incorporated by reference into, and made applicable
to, this Amendment as if set forth herein, mutatis mutandis: Section 4.2 (Amendments and Waivers); Section 4.3 (Notices);
Section 4.5 (Governing Law); Section 4.6 (Severability) and Section 4.7 (Binding Effect; Assignment).

 

[Signature Page Follows]

 

     

     

    

 

The Company and the Investors below named have
caused this Amendment to be executed by their respective officers thereunto duly authorized, in each case as of the date first
written above.

 

	 	CNS Response, Inc.
	 	 
	 	By:	 
	 	 	Name:	Paul Buck
	 	 	Title:	Chief Financial officer

 

	 	MAJORITY HOLDERS:
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature Page to Omnibus Amendment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]